Form 4: Arrowhead Director Lu Hongbo Granted 7,819 RSUs

Arrowhead Pharmaceuticals Director Hongbo Lu was granted 7,819 restricted stock units, vesting in one year, increasing his direct beneficial ownership to 54,982 shares.

Summary

• Director Hongbo Lu of Arrowhead Pharmaceuticals, Inc. (ARWR) acquired 7,819 shares of common stock on December 16, 2025.
• These shares represent restricted stock units (RSUs) granted at a price of $0 per share.
• The RSUs are scheduled to vest in a single installment on the first anniversary of the grant date, contingent upon Mr. Lu's continued service to the Issuer.
• Following this transaction, Mr. Lu directly beneficially owns a total of 54,982 shares of Arrowhead Pharmaceuticals common stock.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a standard compensation practice that aligns the director's interests with long-term shareholder value, indicating continued commitment. This is generally viewed as a neutral to slightly positive event.

Positives

• The grant of restricted stock units aligns Director Hongbo Lu's interests with long-term shareholder value, incentivizing continued commitment to the company's performance.

Risks

• The vesting of the 7,819 restricted stock units is subject to Director Hongbo Lu's continued service to Arrowhead Pharmaceuticals, Inc. on the vesting date.

Future Outlook

The vesting schedule for the restricted stock units implies an expectation of Director Hongbo Lu's continued service to the company for at least one year from the grant date.

Industry Context

The grant of restricted stock units to a director is a standard practice in the biotechnology and pharmaceutical industries for executive and board member compensation, aiming to align leadership incentives with long-term company performance and shareholder interests.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a common form of equity compensation across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, designed to align the interests of board members with long-term shareholder value.
• This practice is consistent with corporate governance best practices for incentivizing leadership and retaining key personnel.

Related Party Transactions

• The grant of restricted stock units to Director Hongbo Lu constitutes a related party transaction, as it involves compensation provided by the issuer to a member of its board of directors. This is a standard and disclosed form of executive and director compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 7,819 restricted stock units are expected to vest on December 16, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a routine grant of restricted stock units to a director as part of their compensation. While it aligns the director's interests with shareholders, it does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation remains appropriate based solely on this filing.

Keywords

Arrowhead Pharmaceuticals, ARWR, Hongbo Lu, Director, Restricted Stock Units, RSU, Stock Grant, Insider Transaction, Form 4, Equity Compensation